SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

[1]  Danielle L. Watt,et al.  Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance , 2016, Proceedings of the National Academy of Sciences.

[2]  R. Levine,et al.  Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. , 2016, Annual review of medicine.

[3]  H. Dombret,et al.  An update of current treatments for adult acute myeloid leukemia. , 2016, Blood.

[4]  V. Hornung,et al.  Phosphorylation of murine SAMHD1 regulates its antiretroviral activity , 2015, Retrovirology.

[5]  Karthik M. Kodigepalli,et al.  Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications , 2015, Molecular Cancer.

[6]  K. Honda,et al.  Aggressive CD8+ epidermotropic cutaneous T-cell lymphoma associated with homozygous mutation in SAMHD1 , 2015, JAAD case reports.

[7]  W. Hiddemann,et al.  An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging , 2015, PloS one.

[8]  H. Urlaub,et al.  FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation. , 2015, Blood.

[9]  N. Ferreirós,et al.  Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry , 2015, Analytical and Bioanalytical Chemistry.

[10]  Mark N. Wass,et al.  Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen , 2015, Scientific Reports.

[11]  I. Taylor,et al.  A Continuous Enzyme-Coupled Assay for Triphosphohydrolase Activity of HIV-1 Restriction Factor SAMHD1 , 2014, Antimicrobial Agents and Chemotherapy.

[12]  A. Gronenborn,et al.  Structural Basis of Allosteric Activation of Sterile α Motif and Histidine-Aspartate Domain-containing Protein 1 (SAMHD1) by Nucleoside Triphosphates* , 2014, The Journal of Biological Chemistry.

[13]  M. Samur.  RTCGAToolbox: A New Tool for Exporting TCGA Firehose Data , 2014, PloS one.

[14]  B. Clotet,et al.  SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[15]  Andrew D. Huber,et al.  SAMHD1 Has Differential Impact on the Efficacies of HIV Nucleoside Reverse Transcriptase Inhibitors , 2014, Antimicrobial Agents and Chemotherapy.

[16]  Michalis K. Titsias,et al.  SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. , 2014, Blood.

[17]  P. Reichard,et al.  The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells , 2013, Proceedings of the National Academy of Sciences.

[18]  James A. Thomson,et al.  Match criteria for human cell line authentication: Where do we draw the line? , 2013, International journal of cancer.

[19]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[20]  A. Gronenborn,et al.  Tetramerization of SAMHD1 Is Required for Biological Activity and Inhibition of HIV Infection , 2013, The Journal of Biological Chemistry.

[21]  B. Nocek,et al.  Nuclease Activity of the Human SAMHD1 Protein Implicated in the Aicardi-Goutières Syndrome and HIV-1 Restriction* , 2013, The Journal of Biological Chemistry.

[22]  R. König,et al.  SAMHD1 restricts HIV-1 infection in resting CD4+ T cells , 2012, Nature Medicine.

[23]  Baek Kim,et al.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates , 2012, Nature Immunology.

[24]  R. Breitling,et al.  Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells , 2011, Cell Death and Disease.

[25]  Geoff Kelly,et al.  HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase , 2011, Nature.

[26]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[27]  M. Washburn,et al.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein , 2011, Nature.

[28]  Augustin Ferrant,et al.  Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.

[29]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Schmidt,et al.  Endogenous CD317/Tetherin Limits Replication of HIV-1 and Murine Leukemia Virus in Rodent Cells and Is Resistant to Antagonists from Primate Viruses , 2010, Journal of Virology.

[31]  T. Gramberg,et al.  Evidence for an Activation Domain at the Amino Terminus of Simian Immunodeficiency Virus Vpx , 2009, Journal of Virology.

[32]  J. Lamba.  Genetic factors influencing cytarabine therapy. , 2009, Pharmacogenomics.

[33]  Y. Crow,et al.  Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. , 2009, Human molecular genetics.

[34]  A. Schambach,et al.  MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. , 2007, Blood.

[35]  J. Gornall.  Where do we draw the line? , 2007, BMJ : British Medical Journal.

[36]  Carlo Riccardi,et al.  Analysis of apoptosis by propidium iodide staining and flow cytometry , 2006, Nature Protocols.

[37]  A. von Deimling,et al.  Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. , 2005, International journal of oncology.

[38]  M. Goldsmith,et al.  Susceptibility of Rat-Derived Cells to Replication by Human Immunodeficiency Virus Type 1 , 2001, Journal of Virology.

[39]  Nan Li,et al.  Identification of human homologue of mouse IFN-γ induced protein from human dendritic cells , 2000 .

[40]  X. Cao,et al.  Identification of human homologue of mouse IFN-gamma induced protein from human dendritic cells. , 2000, Immunology letters.

[41]  H. Preisler,et al.  A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. , 1982, Cancer research.